4//SEC Filing
Danenberg Noam 4
Accession 0001213900-19-006993
CIK 0001218683other
Filed
Apr 22, 8:00 PM ET
Accepted
Apr 23, 6:00 PM ET
Size
14.5 KB
Accession
0001213900-19-006993
Insider Transaction Report
Form 4
Danenberg Noam
Chief Operating Officer
Transactions
- Purchase
Series A Warrants
2019-04-21+125,000→ 125,000 totalExercise: $1.10From: 2019-04-21→ Common Stock (125,000 underlying) - Purchase
Common Stock
2019-04-21$1.00/sh+125,000$125,000→ 165,100 total - Purchase
Investment Rights
2019-04-21+94,382→ 94,382 total(indirect: See footnote)Exercise: $1.33From: 2019-04-21Exp: 2019-11-30→ Common Stock (94,382 underlying) - Purchase
Series B Warrants
2019-04-21+125,000→ 125,000 totalExercise: $1.00From: 2019-04-21→ Common Stock (125,000 underlying) - Purchase
Convertible Loans
2019-04-21+265,531→ 265,531 total(indirect: See footnote)Exercise: $1.11Exp: 2019-05-31→ Common Stock (265,531 underlying)
Footnotes (6)
- [F1]Issuable upon the conversion of the convertible loans under the January 19, 2017 Loan Agreement (the "Loan Agreement") by and among the Issuer and Ridge Valley Corporation, among others. The Convertible Loans may be converted at any time.
- [F2]Mr. Danenberg waived a debt owed to him by Ridge Valley Corporation as consideration for these derivative securities.
- [F3]Held by Mr. Danenberg's wholly-owned company Mobigo Inc.
- [F4]The Series A Warrants expire sixty (60) months after October 23, 2018.
- [F5]Purchased together with the 125,000 shares of Common Stock described in Table I for total purchase price of $125,000.
- [F6]The Series B Warrants expire twenty (20) days following the later of (i) the public announcement of Phase II clinical data for LO2A or (ii) six (6) months following October 23, 2018.
Documents
Issuer
Wize Pharma, Inc.
CIK 0001218683
Entity typeother
Related Parties
1- filerCIK 0001720898
Filing Metadata
- Form type
- 4
- Filed
- Apr 22, 8:00 PM ET
- Accepted
- Apr 23, 6:00 PM ET
- Size
- 14.5 KB